AVALO THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
AVALO THERAPEUTICS, INC. (AVTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.02 million shares for the 12-month period ending 2017-12-31, per its 10-K filed 2018-04-02.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2018-04-02
- AVALO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2017-12-31 was 441.77K shares, a 860.59% increase year-over-year.
- AVALO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2017-09-30 was 210.95K shares, a 31.58% decline year-over-year.
- AVALO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2017-06-30 was 148.64K shares, a 114.85% increase year-over-year.
- AVALO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2017-03-31 was 219.02K shares, a 55.46% decline year-over-year.
- AVALO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2017 was 1.02M shares, a 11.49% increase from fiscal 2016.
- AVALO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2016 was 915.24K shares, a 74.87% increase from fiscal 2015.
- AVALO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2015 was 523.39K shares, a 194.89% increase from fiscal 2014.
- AVALO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2014 was 177.48K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2017-12-31 | 441.77K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | 652.72K shares derived: sum of 2 quarters · filed 2018-04-02 | 801.36K shares derived: sum of 3 quarters · filed 2018-04-02 | 1.02M shares 10-K · filed 2018-04-02 |
| 2017-09-30 | 210.95K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | 359.59K shares derived: sum of 2 quarters · filed 2017-11-07 | 578.61K shares 10-Q · filed 2017-11-07 | 624.60K shares derived: sum of 4 quarters · filed 2018-04-02 |
| 2017-06-30 | 148.64K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | 367.66K shares 10-Q · filed 2017-08-14 | 413.65K shares derived: sum of 3 quarters · filed 2018-04-02 | 721.95K shares derived: sum of 4 quarters · filed 2018-04-02 |
| 2017-03-31 | 219.02K shares 10-Q · filed 2017-05-09 | 265.01K shares derived: sum of 2 quarters · filed 2018-04-02 | 573.31K shares derived: sum of 3 quarters · filed 2018-04-02 | 642.50K shares derived: sum of 4 quarters · filed 2018-04-02 |
| 2016-12-31 | 45.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | 354.29K shares derived: sum of 2 quarters · filed 2018-04-02 | 423.48K shares derived: sum of 3 quarters · filed 2018-04-02 | 915.24K shares 10-K · filed 2018-04-02 |
| 2016-09-30 | 308.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | 377.49K shares derived: sum of 2 quarters · filed 2016-11-08 | 869.25K shares 10-Q · filed 2016-11-08 | 1.32M shares derived: sum of 4 quarters · filed 2017-03-14 |
| 2016-06-30 | 69.19K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | 560.95K shares 10-Q · filed 2016-08-15 | 1.01M shares derived: sum of 3 quarters · filed 2017-03-14 | |
| 2016-03-31 | 491.76K shares 10-Q · filed 2016-05-16 | 942.30K shares derived: sum of 2 quarters · filed 2017-03-14 | ||
| 2015-12-31 | 450.53K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | 523.39K shares 10-K · filed 2017-03-14 | ||
| 2015-09-30 | 72.86K shares 10-Q · filed 2015-11-13 | |||
| 2014-12-31 | 177.48K shares 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |